FrancophonIA/ELRC3.0 huggingface dataset:
English: Week 13 (N=68)
Slovenian: 13. teden (N = 68)
English: Allergic type hypersensitivity reactions have been reported with RIXUBIS.
Slovenian: Poročali so o pojavu preobčutljivostnih reakcij alergijskega tipa po uporabi zdravila RIXUBIS.
English: There have been reports in the literature showing a correlation between the occurrence of a factor IX inhibitor and allergic reactions.
Slovenian: Podatki iz literature navajajo povezavo med pojavnostjo zaviralcev faktorja IX in alergijskimi reakcijami.
English: Adverse reactions Frequency per Patient
Slovenian: Pogostnost na bolnika
English: Kidney disorders (nephrotic syndrome) have been reported following high doses of Factor IX in haemophilia B patients with factor IX inhibitors and a history of allergic reactions.
Slovenian: Objavljena so poročila o bolezni ledvic (nefrotskem sindromu) po dajanju velikih odmerkov faktorja IX bolnikom s hemofilijo B, ki so imeli zaviralce faktorja IX in alergijske reakcije v preteklosti.
English: Incremental recovery for RIXUBIS 30 minutes after infusion, paediatric patients 6 to < 12 years:
Slovenian: Porast aktivnosti faktorja IX po odmerku 30 minut po infuziji zdravila RIXUBIS, pediatrični bolniki od 6 do <12 let:
English: RIXUBIS is provided as a powder and solvent for solution for injection.
Slovenian: RIXUBIS je v obliki praška in vehikla za raztopino za injiciranje.
English: There is a potential risk of thromboembolic episodes following the administration of factor IX products, with a higher risk for low purity preparations.
Slovenian: Pri uporabi pripravkov faktorja IX obstaja tveganje za nastanek tromboemboličnih dogodkov, ki je večje pri pripravkih majhne čistote.
English: Incremental recovery for RIXUBIS 30 minutes after infusion, paediatric patients < 6 years:
Slovenian: Porast aktivnosti faktorja IX po odmerku 30 minut po infuziji zdravila RIXUBIS, pediatrični bolniki <6 let:
English: Your doctor will do a blood test to check if you have developed activity-neutralising antibodies (inhibitors) against RIXUBIS.
Slovenian: Zdravnik bo morda opravil tudi preiskavo krvi, da preveri, ali so se pri vas pojavila protitelesa, ki nevtralizirajo aktivnost zdravila RIXUBIS (zaviralci), saj se lahko sočasno z alergijami pojavijo tudi zaviralci.
English: RIXUBIS contains recombinant coagulation factor IX (nonacog gamma).
Slovenian: Zdravilo RIXUBIS vsebuje rekombinantni koagulacijski faktor IX (nonakog gama).
English: This should be taken into consideration if the patient is on a controlled sodium diet.
Slovenian: To je treba upoštevati pri bolnikih z nadzorovanim vnosom natrija.
English: = body weight (kg) x desired factor IX rise (%) or (IU/dL)
Slovenian: x želeno povečanje faktorja IX (%) ali (i.e./dl)
English: The powder is white to off-white.
Slovenian: Prašek je bel do sivobel.
English: The use of low purity factor IX products has been associated with instances of myocardial infarction, disseminated intravascular coagulation, venous thrombosis and pulmonary embolism.
Slovenian: Uporaba pripravkov faktorja IX majhne čistote je bila povezana s primeri miokardnega infarkta, diseminirane intravaskularne koagulacije, venske tromboze in pljučne embolije, medtem ko je uporaba pripravkov faktorja IX velike čistote le redko povezana s takšnimi neželenimi učinki.
English: Treatment was individualised based on the severity, cause and site of bleed The majority (23; 88,5%) were treated with 1-2 infusions.
Slovenian: Večina (23; 88,5 %) krvavitev je bila zdravljena z 1 do 2 infuzijama.
English: Incremental recovery for RIXUBIS 30 minutes after infusion, both paediatric age groups:
Slovenian: Porast aktivnosti faktorja IX po odmerku 30 minut po infuziji zdravila RIXUBIS za obe pediatrični starostni skupini:
English: What RIXUBIS contains - The active substance is nonacog gamma (recombinant human coagulation Factor IX).
Slovenian: Kaj vsebuje cepivo RIXUBIS - Učinkovina je nonakog gama (rekombinantni humani koagulacijski faktor IX).
English: Patients with haemophilia B may develop neutralising antibodies (inhibitors) to factor IX.
Slovenian: Pri bolnikih s hemofilijo B se lahko pojavijo nevtralizirajoča protitelesa (zaviralci) proti faktorju IX.
English: It should be noted that patients with factor IX inhibitors may be at an increased risk of anaphylaxis with subsequent challenge with factor IX.
Slovenian: Zavedati se je treba, da imajo bolniki z zaviralci faktorja IX povečano tveganje za anafilakso pri naslednji izpostavitvi faktorju IX.
English: Invert the system (the vial with the reconstituted solution has to be on top).
Slovenian: Sistem obrnite tako, da je viala z rekonstituirano raztopino na vrhu.
English: Patients with factor IX inhibitors may be at an increased risk of anaphylaxis during future treatment with factor IX.
Slovenian: Bolniki z zaviralci faktorja IX imajo povečano tveganje za anafilakso pri naslednji uporabi faktorja IX.
English: To ensure that the desired factor IX activity plasma level has been attained, careful monitoring using an appropriate factor IX activity assay is advised and, if necessary, appropriate adjustments to the dose and the frequency of repeated infusions should be performed.
Slovenian: Za zagotovitev želene aktivnosti faktorja IX v plazmi je priporočljivo natančno spremljanje s primernim testom za aktivnost faktorja IX.
English: RIXUBIS 500 IU powder and solvent for solution for injection RIXUBIS 1000 IU powder and solvent for solution for injection RIXUBIS 2000 IU powder and solvent for solution for injection RIXUBIS 3000 IU powder and solvent for solution for injection nonacog gamma (recombinant human coagulation factor IX)
Slovenian: RIXUBIS 500 i.e. prašek in vehikel za raztopino za injiciranje RIXUBIS 1000 i.e. prašek in vehikel za raztopino za injiciranje RIXUBIS 2000 i.e. prašek in vehikel za raztopino za injiciranje RIXUBIS 3000 i.e. prašek in vehikel za raztopino za injiciranje nonakog gama (rekombinantni humani koagulacijski faktor IX)
English: Median (range) Incremental recovery at Cmax (IU/dL:IU/kg)
Slovenian: Povprečje ± SD Mediana (razpon) Porast aktivnosti faktorja IX po odmerku pri Cmax (i.e./dl:i.e./kg)
English: Life-threatening haemorrhages.
Slovenian: Smrtno nevarne krvavitve
English: Week 5 All (N=23)
Slovenian: 5. teden Vsi (N = 23)
English: RIXUBIS contains the active substance nonacog gamma and is a coagulation factor IX product.
Slovenian: Zdravilo RIXUBIS vsebuje učinkovino nonakog alfa in je pripravek koagulacijskega faktorja IX.
English: The required dose is determined using the following formula:
Slovenian: Potrebni odmerek določimo s pomočjo naslednje enačbe: Potrebno št. enot
English: Remove caps from powder and solvent vials.
Slovenian: Z vial s praškom in vehiklom snemite zaporki.
English: Each powder vials contains nominally 250, 500, 1000, 2000 or 3000 IU, corresponding to a concentration of 50, 100, 200, 400 or 600 IU/ml after reconstitution with 5 ml solvent.
Slovenian: Ena viala vsebuje nominalno 250, 500, 1000, 2000 ali 3000 i.e. nonakoga gama, rekombinantnega humanega koagulacijskega faktorja IX (rDNA), kar po rekonstituciji s 5 ml vehikla ustreza koncentraciji 50, 100, 200, 400 ali 600 i.e./ml.
English: Week 5 All (N=12)
Slovenian: 5. teden Vsi (N = 12)
English: Solvent: sterilised water for injections
Slovenian: Vehikel: sterilizirana voda za injekcije
English: Median (range) Clearance (dL/(kg.hr)) Mean±SD
Slovenian: Povprečje ± SD Mediana (razpon) Očistek (dl/(kg.h)) Povprečje ± SD Mediana (razpon)
English: Allergic-type hypersensitivity reactions are possible with RIXUBIS.
Slovenian: Pri uporabi zdravila RIXUBIS je možen pojav preobčutljivostnih reakcij alergijskega tipa.
English: For an incremental recovery of 0.9 IU/dL per IU/kg, the dose is calculated as follows:
Slovenian: Pri porastu aktivnosti faktorja IX po odmerku 0,9 i.e./dl na i.e./kg se odmerek izračuna na naslednji način:
English: How to store RIXUBIS
Slovenian: Shranjevanje zdravila RIXUBIS
English: For an incremental recovery of 0.7 IU/dL per IU/kg, the dose is calculated as follows:
Slovenian: Pri porastu aktivnosti faktorja IX po odmerku 0,7 i.e./dl na i.e./kg se odmerek izračuna na naslednji način:
English: If you get any side effects, talk to your doctor or, pharmacist.
Slovenian: Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom ali farmacevtom.
English: Remove the blue cap from BAXJECT II.
Slovenian: S pripomočka BAXJECT II snemite modri pokrovček.
English: PK (ED 1) All (N=22)
Slovenian: Farmakokinetika (ED 1) Vsi (N = 22)
English: Fig. d
Slovenian: Slika d
English: Please, contact your doctor immediately if you experience such signs.
Slovenian: Če se pri vas pojavijo ti znaki, se nemudoma posvetujte z zdravnikom.
English: PK (ED 1) All (N=10)
Slovenian: Farmakokinetika (ED 1) Vsi (N = 10)
English: PK (ED 1) All (N=12)
Slovenian: Farmakokinetika (ED 1) Vsi (N = 12)
English: Clinical studies of RIXUBIS did not include subjects aged 65 and over.
Slovenian: Osebe, stare 65 let in več, niso bile vključene v klinične študije.
English: Week 5 All (N=11)
Slovenian: 5. teden Vsi (N = 11)
English: VIAL LABEL FOR THE SOLVENT
Slovenian: NALEPKA NA VIALI Z VEHIKLOM
English: After reconstitution, the solution is clear, colourless, free from foreign particles and has a pH of 6.8 to 7.2.
Slovenian: Po rekonstituciji mora biti raztopina bistra, brezbarvna in brez tujkov.
English: Week 26 All (N=21)
Slovenian: 26. teden Vsi (N = 21)
English: Solvent Sterilised water for injections
Slovenian: Vehikel sterilizirana voda za injekcije
English: Week 13 All (N=21)
Slovenian: 13. teden Vsi (N = 21)
English: The calculation of the required dose of factor IX is based on the empirical finding that 1 International Unit factor IX per kg body weight raises the plasma factor IX activity by 0.9 IU/dL (range from 0.5 to 1.4 IU/dL) or 0.9% of normal activity in patients 12 years and older (further information see section 5.2).
Slovenian: Izračun potrebnega odmerka faktorja IX temelji na empiričnih izkušnjah, da 1 mednarodna enota faktorja IX na kg telesne mase pri bolnikih, starih 12 let in več, zviša aktivnost faktorja IX v plazmi za 0,9 i.e./dl (razpon od 0,5 do 1,4 i.e./dl) ali 0,9 % normalne aktivnosti (za več informacij glejte poglavje 5.2).
English: Week 26 All (N=10)
Slovenian: 26. teden Vsi (N = 10)
English: The calculation of the required dose of factor IX is based on the empirical finding that 1 International Unit factor IX per kg body weight raises the plasma factor IX activity by 0.7 IU/dL (range from 0.31 to 1.0 IU/dL) or 0.7% of normal activity in patients less than 12 years of age (further information see section 5.2).
Slovenian: Izračun potrebnega odmerka faktorja IX temelji na empiričnih izkušnjah, da 1 mednarodna enota faktorja IX na kg telesne mase pri bolnikih, mlajših od 12 let, zviša aktivnost faktorja IX v plazmi za 0,7 i.e./dl (razpon od 0,31 do 1,0 i.e./dl) ali 0,7 % normalne aktivnosti (za več informacij glejte poglavje 5.2).
English: The calculation of the required dose of factor IX is based on the empirical finding that 1 International Unit (IU) factor IX per kg body weight raises the plasma factor IX activity by 0.7 IU/dL (range from 0.31 to 1.0 IU/dL) or 0.7% of normal activity in patients less than 12 years of age (further information see section 5.2).
Slovenian: Izračun potrebnega odmerka faktorja IX temelji na empiričnih izkušnjah, da 1 mednarodna enota (i.e.) faktorja IX na kg telesne mase pri bolnikih, mlajših od 12 let, zviša aktivnost faktorja IX v plazmi za 0,7 i.e./dl (razpon od 0,31 do 1,0 i.e./dl) ali 0,7 %normalne aktivnosti (za več informacij glejte poglavje 5.2).
English: Week 13 All (N=11)
Slovenian: 13. teden Vsi (N = 11)
English: Week 13 All (N=10)
Slovenian: 13. teden Vsi (N = 10)
English: Week 26 All (N=11)
Slovenian: 26. teden Vsi (N = 11)
English: Median (range) Cmax (IU/dL) Mean±SD
Slovenian: Povprečje ± SD Mediana (razpon) Razpolovna doba (h) Povprečje ± SD Mediana (razpon) Cmax (i.e./dl)
English: Nephrotic syndrome has been reported following attempted immune tolerance induction in haemophilia B patients with factor IX inhibitors and a history of allergic reactions.
Slovenian: Pri poskusu indukcije imunske tolerance pri bolnikih s hemofilijo B, ki so imeli zaviralce faktorja IX in alergijske reakcije v anamnezi, so poročali o nefrotskem sindromu.
English: Nephrotic syndrome has been reported following attempted immune tolerance induction in haemophilia B patients with factor IX inhibitors.
Slovenian: Pri poskusu indukcije imunske tolerance pri bolnikih s hemofilijo B, ki so imeli zaviralce faktorja IX, so poročali o nefrotskem sindromu.
English: RIXUBIS 500 IU powder for injection nonacog gamma
Slovenian: RIXUBIS 500 i.e. prašek za injiciranje nonakog gama i.v.
English: RIXUBIS 250 IU powder for injection nonacog gamma
Slovenian: RIXUBIS 250 i.e. prašek za injiciranje nonakog gama i.v.
English: Fig. a
Slovenian: Slika a
English: Median (range)
Slovenian: = telesna masa (kg)
English: RIXUBIS 2000 IU powder for injection nonacog gamma
Slovenian: RIXUBIS 2000 i.e. prašek za injiciranje nonakog gama i.v.
English: RIXUBIS 250 IU powder and solvent for solution for injection nonacog gamma (recombinant human coagulation factor IX)
Slovenian: RIXUBIS 250 i.e. prašek in vehikel za raztopino za injiciranje nonakog gama (rekombinantni humani koagulacijski faktor IX)
English: RIXUBIS 500 IU powder and solvent for solution for injection One vial contains nominally 500 IU nonacog gamma, recombinant human coagulation factor IX (rDNA), corresponding to a concentration of 100 IU/ml after reconstitution with 5 ml solvent.
Slovenian: RIXUBIS 500 i.e. prašek in vehikel za raztopino za injiciranje Ena viala vsebuje nominalno 500 i.e. nonakoga gama, rekombinantnega humanega koagulacijskega faktorja IX (rDNA), kar po rekonstituciji s 5 ml vehikla ustreza koncentraciji 100 i.e./ml.
English: RIXUBIS 2000 IU powder and solvent for solution for injection One vial contains nominally 2000 IU nonacog gamma, recombinant human coagulation factor IX (rDNA), corresponding to a concentration of 400 IU/ml after reconstitution with 5 ml solvent.
Slovenian: RIXUBIS 2000 i.e. prašek in vehikel za raztopino za injiciranje Ena viala vsebuje nominalno 2000 i.e. nonakoga gama, rekombinantnega humanega koagulacijskega faktorja IX (rDNA), kar po rekonstituciji s 5 ml vehikla ustreza koncentraciji 400 i.e./ml.
English: RIXUBIS 500 IU powder and solvent for solution for injection nonacog gamma (recombinant human coagulation factor IX)
Slovenian: RIXUBIS 500 i.e. prašek in vehikel za raztopino za injiciranje nonakog gama (rekombinantni humani koagulacijski faktor IX)
English: RIXUBIS 3000 IU powder and solvent for solution for injection One vial contains nominally 3000 IU nonacog gamma, recombinant human coagulation factor IX (rDNA), corresponding to a concentration of 600 IU/ml after reconstitution with 5 ml solvent.
Slovenian: RIXUBIS 3000 i.e. prašek in vehikel za raztopino za injiciranje Ena viala vsebuje nominalno 3000 i.e. nonakoga gama, rekombinantnega humanega koagulacijskega faktorja IX (rDNA), kar po rekonstituciji s 5 ml vehikla ustreza koncentraciji 600 i.e./ml.
English: RIXUBIS 1000 IU powder and solvent for solution for injection One vial contains nominally 1000 IU nonacog gamma, recombinant human coagulation factor IX (rDNA), corresponding to a concentration of 200 IU/ml after reconstitution with 5 ml solvent.
Slovenian: RIXUBIS 1000 i.e. prašek in vehikel za raztopino za injiciranje Ena viala vsebuje nominalno 1000 i.e. nonakoga gama, rekombinantnega humanega koagulacijskega faktorja IX (rDNA), kar po rekonstituciji s 5 ml vehikla ustreza koncentraciji 200 i.e./ml.
English: RIXUBIS 1000 IU powder for injection nonacog gamma
Slovenian: RIXUBIS 1000 i.e. prašek za injiciranje nonakog gama i.v.
English: RIXUBIS 3000 IU powder for injection nonacog gamma
Slovenian: RIXUBIS 3000 i.e. prašek za injiciranje nonakog gama i.v.
English: RIXUBIS 2000 IU powder and solvent for solution for injection nonacog gamma (recombinant human coagulation factor IX)
Slovenian: RIXUBIS 2000 i.e. prašek in vehikel za raztopino za injiciranje nonakog gama (rekombinantni humani koagulacijski faktor IX)
English: RIXUBIS 250 IU powder and solvent for solution for injection One vial contains nominally 250 IU nonacog gamma, recombinant human coagulation factor IX (rDNA), corresponding to a concentration of 50 IU/ml after reconstitution with 5 ml solvent.
Slovenian: KAKOVOSTNA IN KOLIČINSKA SESTAVA RIXUBIS 250 i.e. prašek in vehikel za raztopino za injiciranje Ena viala vsebuje nominalno 250 i.e. nonakoga gama, rekombinantnega humanega koagulacijskega faktorja IX (rDNA), kar po rekonstituciji s 5 ml vehikla ustreza koncentraciji 50 i.e./ml.
English: RIXUBIS 3000 IU powder and solvent for solution for injection nonacog gamma (recombinant human coagulation factor IX)
Slovenian: RIXUBIS 3000 i.e. prašek in vehikel za raztopino za injiciranje nonakog gama (rekombinantni humani koagulacijski faktor IX)
English: Median (range) Mean residence time (hr) Mean±SD
Slovenian: Povprečje ± SD Mediana (razpon) Povprečni čas zadrževanja (h) Povprečje ± SD Mediana (razpon)
English: RIXUBIS 1000 IU powder and solvent for solution for injection nonacog gamma (recombinant human coagulation factor IX)
Slovenian: RIXUBIS 1000 i.e. prašek in vehikel za raztopino za injiciranje nonakog gama (rekombinantni humani koagulacijski faktor IX)
English: RIXUBIS is administered by intravenous infusion (IV) after reconstitution of the powder with the provided solvent by your doctor or nurse.
Slovenian: po rekonstituciji praška s priloženim vehiklom, kar opravi zdravnik ali medicinska sestra.
English: Powder
Slovenian: Krvavitev
English: Posology
Slovenian: uporaba
English: Median (range) Half-life (hr) Mean±SD
Slovenian: Očistek (dl/(kg.h)) Povprečje ± SD Mediana (razpon)
English: Fig. e
Slovenian: Slika e
English: 70 or more
Slovenian: 70 ali več
English: 4.8 Undesirable effects a) Summary of the safety profile
Slovenian: 4.8 Neželeni učinki a) Povzetek varnostnega profila
English: • are more than 70 years old.
Slovenian: • ste starejši od 70 let,
English: • heart attack in the last 3 to 6 months;
Slovenian: • srčno kap v zadnjih 3 do 6 mesecih,
English: The rate of injection should be very slow (1 ml/min).
Slovenian: Hitrost injiciranja mora biti zelo počasna (1 ml/min).
English: This leaflet was last revised in {month YYYY}.
Slovenian: Navodilo je bilo nazadnje revidirano {mesec LLLL}.
English: There is no experience of the use of articaine in pregnant women, except during childbirth.
Slovenian: Ni izkušenj z uporabo artikaina pri nosečnicah, razen med porodom.
English: Mechanism of action and pharmacodynamic effects:
Slovenian: Mehanizem delovanja in farmakodinamični učinki:
English: The pKa of articaine has been estimated at 7.8.
Slovenian: Vrednost pKa za artikain je ocenjena na 7,8.
English: Since this hydrolysis is very fast, about 90% of articaine is inactivated by this way.
Slovenian: Ker je hidroliza zelo hitra, se približno 90 % artikaina inaktivira na ta način.
English: Serious adverse reactions are generally systemic.
Slovenian: Resni neželeni učinki so običajno sistemski.
English: The higher risk of bleeding is more associated with the procedure, rather than with the medicine.
Slovenian: Večje tveganje za krvavitve je bolj povezano s postopkom posega kot z zdravilom.
English: • double vision, temporary blindness
Slovenian: • dvojni vid, začasna slepota,
English: Careful aspiration prior to administration is recommended.
Slovenian: Pred aplikacijo je priporočljiva skrbna aspiracija.
English: d) Paediatric population
Slovenian: d) Pediatrična populacija
English: Renal elimination of unchanged articaine accounted for only about 2% of total elimination.
Slovenian: Nespremenjenega artikaina se preko ledvic izloči le približno 2 % od celotnega izločanja.
English: You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of these medicines.
Slovenian: O neželenih učinkih lahko poročate tudi neposredno na nacionalni center za poročanje, ki je naveden v Prilogi V. S tem, ko poročate o neželenih učinkih, lahko prispevate k zagotovitvi več informacij o varnosti tega zdravila.
English: Within 24 hours, approximately 57% (68 mg) and 53% (204 mg) of the dose was eliminated in the urine.
Slovenian: V 24 urah se je približno 57 % (68 mg) in 53 % (204 mg) odmerka izločilo z urinom.
English: ATC code: N01BB58
Slovenian: artikain, kombinacije; oznaka ATC: N01BB58
English: While you are in your dentist's office, your dentist will carefully follow the effects of X / Y.
Slovenian: Dokler boste v zobozdravniški ordinaciji, bo zobozdravnik skrbno nadziral učinke zdravila X/Y.
English: • increased sensitivity to heat
Slovenian: • povečana občutljivost za vročino,
English: Depending on the kind of dental procedure performed, the dentist will choose between the two medicines:
Slovenian: Odvisno od vrste zobozdravstvenega posega bo zobozdravnik izbral med dvema zdraviloma:
English: Your dentist knows how to throw away medicines no longer used.
Slovenian: Zobozdravnik je seznanjen z načinom odstranjevanja zdravila, ki se ne uporablja več.
English: Tell your dentist if you are taking, have recently taken or might take any other medicines.
Slovenian: Obvestite zobozdravnika, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
English: This medicine contains two active substances:
Slovenian: Zdravilo vsebuje dve učinkovini:
English: Adrenaline passes into breast milk but also has a short half-life.
Slovenian: Adrenalin prehaja v materino mleko, vendar ima tudi kratek razpolovni čas.
English: It also decreases bleeding during surgery.
Slovenian: Zmanjša tudi krvavitev med kirurškim posegom.
English: • articaine, a local anaesthetic which prevents pain, and
Slovenian: • artikain, lokalni anestetik, ki prepreči bolečino, in
English: Dental use.
Slovenian: Dentalna uporaba.
English: The table below illustrates the maximum recommended dose:
Slovenian: V spodnji tabeli so navedeni največji priporočeni odmerki:
English: It is especially important to tell your dentist if you are taking any of the following medicines:
Slovenian: Še posebej je pomembno, da obvestite svojega zobozdravnika, če jemljete katero koli od naslednjih zdravil:
English: Adrenaline exhibits sympathomimetic effects.
Slovenian: Adrenalin kaže simpatikomimetične učinke.
English: The dose must also be reduced in case of hypoxia, hyperkalaemia and metabolic acidosis.
Slovenian: Odmerek je treba zmanjšati tudi v primeru hipoksije, hiperkaliemije in metabolične acidoze.
English: The quantity to be injected should be determined by the age and weight of the child and the magnitude of the operation.
Slovenian: Količino zdravila, ki bo vbrizgana, je treba določiti glede na starost in težo otroka ter obširnosti operacije.
English: • increased, unpleasant or abnormal sense of touch
Slovenian: • povečan, neprijeten ali nenormalen čut za dotik,
English: Use immediately after the opening of the cartridge.
Slovenian: Uporabite takoj po odprtju vložka.
English: Binding to γ-globulin (8.6-23.7%) was much lower.
Slovenian: Vezava na γ-globulin je bila mnogo manjša (8,6 do 23,7 %).
English: • Articaine
Slovenian: • Artikain
English: Concomitant use of sedatives to reduce patient anxiety:
Slovenian: Sočasna uporaba pomirjeval za zmanjšanje anksioznosti bolnika:
English: These medicines may intensify the effects of adrenaline.
Slovenian: Ta zdravila lahko okrepijo učinke adrenalina.
English: Children should be given doses commensurate with age and weight.
Slovenian: Otrokom je treba dati odmerek, ki ustreza njihovi starosti in teži.
English: • ringing of the ears, over-sensitivity of hearing
Slovenian: • zvenenje v ušesih, prevelika občutljivost sluha,
English: Most cases of paresthesia reported following dental treatment are transient and resolve within days, weeks or months.
Slovenian: Večina primerov parestezije, o katerih so poročali po zobozdravstvenih posegih, je bilo prehodnih in so izzveneli v dneh, tednih ali mesecih.
English: Elderly patients:
Slovenian: Starejši bolniki